Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Hematology

Building Your Care Team & First Visit Prep

At a Glance

Because AL amyloidosis affects multiple organs, it requires a multidisciplinary care team led by a hematologist, alongside cardiologists and other specialists. For your first visit to a specialized center, always bring your original biopsy slides, recent heart labs, and imaging discs.

AL amyloidosis is a “team sport” disease. Because amyloid fibrils can deposit in multiple organs, no single doctor can manage it alone [1][2]. Research shows that patients who receive care from a multidisciplinary team at a high-volume center have better survival outcomes than those treated in isolation [3][4].

Your Multidisciplinary Team

A complete care team for AL amyloidosis should include specialists who communicate with each other regularly [5][6]:

  • Hematologist/Oncologist: The “captain” of the team. They manage the plasma cell dyscrasia (the source of the problem) and prescribe the chemotherapy or immunotherapy [5].
  • Cardiologist (specifically Cardio-Oncology): Heart involvement is the primary driver of survival [7]. You need a cardiologist who understands how amyloidosis stiffens heart muscle and how to protect the heart during treatment [6][8].
  • Nephrologist: If you have protein in your urine, a kidney specialist is essential to manage fluid balance and monitor kidney function [1].
  • Neurologist: Necessary if you experience numbness, “pins and needles,” or dizziness when standing (autonomic neuropathy) [9][10].
  • Nurse Navigator: A dedicated coordinator who acts as your single point of contact, ensuring your labs and records are shared between all specialists [11].

Vetting Your Team: Questions to Ask

Because AL amyloidosis is rare, “volume” matters. You should not be your doctor’s first or second amyloidosis patient [11]. When choosing a specialist, consider asking:

  • “Do you use Mass Spectrometry for typing?” Accurate typing is mandatory for early, correct therapy [12][13].
  • “How many AL amyloidosis patients are currently in your practice?” Specialized centers typically see a high volume of cases annually [3].
  • “Do you have access to clinical trials?” Academic centers often offer access to new therapies before they are widely available [14].

Your First Visit Toolkit

To make the most of your first appointment at a center of excellence, you must bring the physical “artifacts” of your diagnosis [12]. Do not assume your electronic records will transfer automatically [15].

What to Bring:

  1. Biopsy Materials: Request the “glass slides” and “paraffin blocks” from the pathology lab where your biopsy was first performed. The new center will want to “re-read” these slides [12].
  2. Laboratory Baseline: A printed copy of your most recent sFLC (free light chains), NT-proBNP, and Troponin levels [16][7].
  3. Cardiac Imaging: A disc (CD/DVD) or digital link containing your most recent Echocardiogram (specifically looking for “strain” or GLS) or Cardiac MRI [7][8].
  4. Complete Medication List: Include all supplements, as some can interfere with heart markers or blood pressure management [2].
  5. A Support Person: Bring a trusted friend or family member to take notes. “Scanxiety” and the sheer volume of information can be overwhelming, so having a designated note-taker is highly practical.

Finding an Expert Center

Look for centers that are members of the Amyloidosis Foundation or the Amyloidosis Research Consortium (ARC) network. These institutions are recognized for having the multidisciplinary infrastructure and advanced diagnostics (like mass spectrometry) required to manage this complex disease [4][11].

Common questions in this guide

Which doctors should be on my AL amyloidosis care team?
Your core team should include a hematologist or oncologist to manage the underlying disease, along with a cardiologist, nephrologist, and neurologist to manage specific organ involvement. A nurse navigator is also highly recommended to coordinate your care and share records.
Why do I need to see a cardio-oncologist for AL amyloidosis?
Heart involvement is the most critical factor in AL amyloidosis outcomes. A cardio-oncologist specializes in protecting your heart muscle during chemotherapy and understands how amyloid proteins specifically stiffen the heart.
What should I bring to my first amyloidosis specialist appointment?
Bring your original biopsy glass slides and paraffin blocks for a second opinion at the new center. You should also bring printed copies of recent lab results like free light chains and heart markers, cardiac imaging discs, and a complete medication list.
Why is mass spectrometry important for diagnosing amyloidosis?
Mass spectrometry is the most accurate and reliable test for typing amyloidosis. Precise typing is essential because different types of amyloidosis require completely different treatments, ensuring you get the correct therapy as early as possible.
How do I find an AL amyloidosis center of excellence?
Look for medical institutions affiliated with the Amyloidosis Foundation or the Amyloidosis Research Consortium. These specialized centers see a high volume of patients and have the multidisciplinary experts and advanced testing required to manage this complex disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many new patients with AL amyloidosis do you personally treat each year?
  2. 2.Is there a 'Cardio-Oncology' specialist on my team who understands how chemotherapy affects amyloid-involved hearts?
  3. 3.Do you have a dedicated nurse navigator or coordinator to help me manage appointments across different specialties?
  4. 4.Does this facility perform Mass Spectrometry for amyloid typing, or do you send samples out to a reference lab like the Mayo Clinic?
  5. 5.Will my specialists meet together (in a 'tumor board' or multidisciplinary meeting) to discuss my specific case?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.

    Muchtar E, Dispenzieri A, Gertz MA, et al.

    Mayo Clinic proceedings 2021; (96(6)):1546-1577 doi:10.1016/j.mayocp.2021.03.012.

    PMID: 34088417
  2. 2

    Supportive Care in AL Amyloidosis.

    Cibeira MT, Ortiz-Pérez JT, Quintana LF, et al.

    Acta haematologica 2020; (143(4)):335-342 doi:10.1159/000506760.

    PMID: 32235118
  3. 3

    [Monoclonal gammapathy of renal significance (MGRS) at the current state: terminology, diagnosis and treatment].

    Lysenko Kozlovskaya LV, Rameev VV, Androsova TV

    Terapevticheskii arkhiv 2020; (92(6)):15-22 doi:10.26442/00403660.2020.06.000666.

    PMID: 33346488
  4. 4

    Systemic amyloidosis journey from diagnosis to outcomes: a twelve-year real-world experience of a single center in a middle-income country.

    Szor RS, Fernandes F, Lino AMM, et al.

    Orphanet journal of rare diseases 2022; (17(1)):425 doi:10.1186/s13023-022-02584-3.

    PMID: 36471404
  5. 5

    Targeted treatments of AL and ATTR amyloidosis.

    Chandrashekar P, Desai AK, Trachtenberg BH

    Heart failure reviews 2022; (27(5)):1587-1603 doi:10.1007/s10741-021-10180-z.

    PMID: 34783948
  6. 6

    Cardiovascular toxicity from therapies for light chain amyloidosis.

    Morfino P, Aimo A, Castiglione V, et al.

    Frontiers in cardiovascular medicine 2023; (10()):1212983 doi:10.3389/fcvm.2023.1212983.

    PMID: 37476571
  7. 7

    Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters.

    Lei C, Zhu X, Hsi DH, et al.

    BMC cardiovascular disorders 2021; (21(1)):43 doi:10.1186/s12872-021-01856-3.

    PMID: 33478398
  8. 8

    Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.

    Pun SC, Landau HJ, Riedel ER, et al.

    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2018; (31(1)):64-70 doi:10.1016/j.echo.2017.08.017.

    PMID: 29111123
  9. 9

    Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group.

    Mauermann ML, Clarke JO, Litchy WJ, et al.

    Advances in therapy 2023; (40(11)):4695-4710 doi:10.1007/s12325-023-02637-4.

    PMID: 37658177
  10. 10

    Light-Chain Amyloidosis With Peripheral Neuropathy as an Initial Presentation.

    Qian M, Qin L, Shen K, et al.

    Frontiers in neurology 2021; (12()):707134 doi:10.3389/fneur.2021.707134.

    PMID: 34650504
  11. 11

    World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).

    Brito D, Albrecht FC, de Arenaza DP, et al.

    Global heart 2023; (18(1)):59 doi:10.5334/gh.1262.

    PMID: 37901600
  12. 12

    Amyloidosis of the Heart and Kidney.

    Adrogue HE

    Methodist DeBakey cardiovascular journal 2022; (18(4)):27-33 doi:10.14797/mdcvj.1150.

    PMID: 36132587
  13. 13

    Combined Subcutaneous Fat Aspirate and Skin Tru-Cut Biopsy for Amyloid Screening in Patients with Suspected Systemic Amyloidosis.

    Hansen CT, Møller HEH, Rojek AM, et al.

    Molecules (Basel, Switzerland) 2021; (26(12)) doi:10.3390/molecules26123649.

    PMID: 34203841
  14. 14

    Amyloidosis in Heart Failure.

    Ihne S, Morbach C, Obici L, et al.

    Current heart failure reports 2019; (16(6)):285-303 doi:10.1007/s11897-019-00446-x.

    PMID: 31782077
  15. 15

    A Blockchain Framework for Patient-Centered Health Records and Exchange (HealthChain): Evaluation and Proof-of-Concept Study.

    Hylock RH, Zeng X

    Journal of medical Internet research 2019; (21(8)):e13592 doi:10.2196/13592.

    PMID: 31471959
  16. 16

    Warning values of serum total kappa/lambda ratio for M-proteinemia.

    Lu J, Zhu Y, Huang H, et al.

    BMC immunology 2024; (25(1)):73 doi:10.1186/s12865-024-00664-6.

    PMID: 39478462

This page provides educational information about assembling a care team for AL amyloidosis. Always consult with your primary hematologist or oncologist for specific medical advice, care coordination, and referrals.

Get notified when new evidence is published on AL amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.